Table 2 Variations of the main characteristics after one year of ETI.

From: Improvement of iron status with elexacaftor tezacaftor ivacaftor therapy is associated with the correction of systemic inflammation and improvement of lung function: a one-year prospective study

 

V0 (n = 220)

V12 (n = 220)

p

Iron deficiency (n, %)

126 (58%)

68 (31%)

0.001

BMI

(kg.m− 2, median [Q1;Q3])

20.8 [19; 22.9]

22.1 [20.5; 23.7]

< 0.001

Diabetes (%)

24%

22%

ns

Glycaemia (mmol/L)

5.1 [4.6; 5.4]

5 [4.6; 5.3]

ns

PPI use (n, %)

84 (38%)

77 (35%)

0.38

Pseudomonas aeruginosa colonization (n, %)

143 (64%)

95 (43%)

< 0.001

Haemoglobin

(g/dL, median [Q1;Q3])

14.4 [13.1; 15.4]

14.6 [13.6; 15.4]

ns

Anaemia (n, %)

27 (12.7%)

11 (5.1%)

0.006

Ferritin

(µg/L, median [Q1;Q3])

46 [26.5; 85.5]

53 [30.3; 97.8]

0.002

TSAT (%)

17 [12; 24]

24 [17; 29.8]

< 0.001

CRP (mg/L)

5.3 [2; 13.8]

1 [0.4; 2.7]

< 0.001

Globulin (g/L)

12.7 [10.6. 15]

10.9 [9.4; 12.6]

< 0.001

Vitamin D (ng/mL)

60.5 [39.3; 75.9]

70 [51.3; 88]

< 0.001

FEV1p (%, median [Q1;Q3]

59 [44; 77]

80 [61; 96]

< 0.001

FEV1 (n, %)

- > 69%

- 50–69%

- 30–49%

- < 30%

82 (38.5%)

60 (28.2%)

61 (28.6%)

10 (4.7%)

141 (66.2%)

46 (21.6%)

23 (10.8%)

3 (1.4%)

< 0.001